Key takeaways
Generic Entresto is now available and FDA approved.
Brand-name and generic Entresto are equally effectiv
The Entreso generic offers significant cost savings.
Entresto is a brand-name prescription drug that is FDA-approved to treat congestive heart failure. Entresto contains two active ingredients, sacubitril and valsartan, that work by relaxing blood vessels and reducing blood pressure. The combination of these two components is unique, making Entresto the first medication in a new class of drugs called angiotensin receptor neprilysin inhibitors (ARNIs).
Like most brand-name drugs, Entresto is more expensive than generic alternatives. Fortunately, generic Entresto was recently approved by the FDA and is now available at pharmacies across the country. Continue reading to learn more about Entresto and its generic version, which is often significantly cheaper than the brand-name version.
Is there a generic for Entresto?
Yes, generic Entresto is now available. Entresto generics, sold simply as sacubitril-valsartan tablets, were approved in May 2024 but only hit U.S. pharmacy shelves in July 2025. “It has very good supply with a couple of different generic drug companies,” says Blair Gingerich, Pharm.D., an ambulatory care pharmacist in northern Indiana and a member of the SingleCare Medical Board.
What are the differences between brand-name and generic Entresto?
Minor differences between brand-name and generic Entresto may include:
- The drug manufacturer. Novartis Pharmaceuticals Corporation makes Entresto. Generic Entresto is made by a variety of drug companies.
- Cost. Generic drugs usually cost less than brand-name drugs.
- Appearance. “Tablets may look different, but the active meds are the same,” says Barbara Sparacino, MD, a triple board-certified geriatric psychiatrist, addiction medicine specialist, and founder of The Aging Parent Coach.
There is very little difference between brand-name and generic Entresto. The FDA requires generic drugs to have the same dosage, side effects, safety, and effectiveness as their brand-name equivalents. Like brand-name Entresto, generic Entresto is still an ARNI that combines the neprilysin inhibitor sacubitril with the angiotensin receptor blocker (ARB) valsartan and is FDA approved to reduce the risk of cardiovascular events in adult patients with chronic heart failure and to treat certain types of symptomatic heart failure in children and adolescents 1 year and older.
It’s important to understand that the interchangeability of brand-name and generic drugs is backed by science. A research analysis of eight brand-name and prescription medications and 2,264,774 matched pairs of patients found that generics resulted in “comparable clinical outcomes” to their brand-name counterparts. However, one study of antidepressants did find that brand-name drugs outperformed their generic equivalents.
Bottom line: Talk to your healthcare provider if you are interested in switching from brand-name Entresto to its generic form. Your prescriber can talk through any questions or concerns. When her own patients make the switch, Dr. Sparacino double-checks dosage and asks patients to report back if anything feels “off.” “If a patient had a very specific clinical response [to the brand-name medication] and is anxious about a switch, we can individualize—but most do well switching to save money,” she says.
| Entresto (sacubitril-valsartan) | |
| Uses |
|
| Standard dosage |
|
| Common side effects |
|
| Contraindications |
|
| Other considerations |
|
How much is generic Entresto?
The price of generic Entresto varies depending on dosage, quantity, insurance coverage, pharmacy, and location. In general, generic versions of Entresto can be cheaper than brand-name Entresto even when insurance doesn’t cover some or all of the cost.
Currently, the average retail price of generic Entresto is $459 for 60, 24-26 mg tablets, whereas the average price of brand-name Entresto is $969 for 60, 24-26 mg tablets, which is a one-month supply of a starting dose. Cash payers can pay as little as $50 for 60, 24-26mg tablets of generic sacubitril-valsartan by using SingleCare coupons or a SingleCare discount card at CVS.
Brand vs. generic Entresto prices |
||
|---|---|---|
| Brand-name Entresto | Entresto generic | |
| Average cost without insurance | $969 for 60, 24-26 mg tablets of Entresto | $459 per 60, 24-26 mg tablets of sacubitril-valsartan |
| SingleCare’s lowest price | $691 for 60, 24-26 mg tablets of Entresto at Walgreens | $50 for 60, 24-26 mg tablets of sacubitril-valsartan at CVS |
| Free coupons | Entresto coupons | Sacubitril-Valsartan coupons |
Prescription drug prices often change. These are the most accurate medication prices at the time of publishing in ZIP code 23666 as of November 4, 2005. The listed price without insurance references the price of brand-name drugs (unless otherwise specified). The listed SingleCare price references the price of generic drugs if available.
Save up to 80% on Entresto with SingleCare
Different pharmacies offer different prices for the same medication. SingleCare helps find the best price for you.
Is Entresto covered by insurance?
Insurance coverage can drastically reduce the out-of-pocket cost of brand-name and generic prescription drugs. The good news is that many commercial insurance plans and Medicare Part D plans cover Entresto, though each person’s final price will depend on their plan’s deductible and copay.
Heart failure patients without insurance coverage for Entresto may still be able to save on Entresto by switching to the generic form, using coupons, or participating in financial assistance programs. “I advise patients to ask the pharmacist to order by the generic name, not ‘Entresto,’ and to check coupon pricing while they wait,” Dr. Sparacino says.
Generic alternatives to Entresto
Entresto is a first-of-its-kind medication, so the only true Entresto alternative is sacubitril-valsartan, which is generic Entresto itself. Other generic heart medications include beta blockers, ACE inhibitors, and ARBs such as:
The good news is that with the new availability of generic Entresto, patients with a prescription for Entresto can now ask their pharmacists to dispense sacubitril-valsartan instead. “If a pharmacy can order it, the order will arrive next business day, “ says Dr. Gingerich. “With how many people need this medication, pharmacies should have sufficient supply on the shelves at any given time.”
A drug shortage of Entresto is unlikely since several pharmaceutical companies are manufacturing the generic form. Anyone who thinks they might have trouble filling their prescription or accessing more Entresto when their current supply runs out should contact their prescriber. Stopping Entresto should not cause withdrawal symptoms, but there is a risk of worsening cardiovascular symptoms and rebound high blood pressure, which can be dangerous and even deadly in people with chronic heart failure.
Bottom line: Entresto was the first drug in a new class of powerful heart failure drugs, but as a brand-name drug, it came at a high price. Fortunately, a lower-cost generic version of Entresto is now available. If you’re interested in switching from brand-name Entresto to generic Entresto, seek medical advice from a healthcare provider who knows your medical history, health conditions, and other prescription and over-the-counter medications.
- FDA roundup: May 31, 2024, U.S. Food and Drug Administration (2024)
- Novartis cannot block generic version of Entresto, judge rules, Reuters (2025)
- The same medicine can come in different shapes and sizes, UCLA Health (2022)
- Highlights of prescribing information: ENTRESTO® (sacubitril and valsartan) tablets, for oral use, FDA (2024)
- Generic drugs: Questions and answers, FDA
- Sacubirtril and valsartan tablet, film coated, DailyMed (2025)
- Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims, PLOS Medicine (2019)
- Brand-name antidepressants outperform their generic counterparts in preventing hospitalization for depression: The real-world evidence from Taiwan, International Journal of Neuropsychopharmacology (2020)
- The impact of discontinuation of sacubitril-valsartan and shifting to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in patients with heart failure with reduced ejection fraction, The Anatolian Journal of Cardiology (2021)
- Blair Gingerich, Pharm.D., an ambulatory care pharmacist and a member of the SingleCare Medical Board
- Barbara Sparacino, MD, a triple board-certified geriatric psychiatrist, addiction medicine specialist, and founder of The Aging Parent Coach